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http://www.diagnosticpathology.org/content/8/1/20CASE REPORT Open AccessUnusual cutaneous Langerhans cell sarcoma
without extracutaneous involvement
Yang Li1†, Bin Li1†, Xiao-ying Tian2 and Zhi Li1*Abstract: Langerhans cell sarcoma (LCS) typically presents as cytologic atypia and clinical aggressiveness and may
involve multiple organs during the progression of the disease. Primary skin LCS without any extra-cutaneous site
association is extremely rare and only a few such cases have been described in the literature. We present a case of
unusual primary LCS in skin occurring in a middle-aged male patient. Physical examination revealed a large
ulcerated cutaneous lesion and a smaller nodular lesion were located in the skin of the extensor side of his right
knee. There was no regional lymph node or any other extra-cutaneous organ involvement. Histologically, typical
large and pleomorphological tumor cells with epithelioid appearance and significantly malignant cytological
features were observed to infiltrate in dermis and subcutaneous tissue. By immunohistochemistry, the tumor cells
were positive for CD1a, S-100 protein and largerin strongly and diffusely. However, these cells were negative for
CD3, CD20, CD21, pan-cytokeratin, HMB-45, Melan-A, and MPO. A diagnosis of primary cutaneous LCS was made.
The patient received systemic chemotherapy of CHOP regimen, and was on a regular follow-up period for 12
months. There was no sign of relapse of tumor or any other extra-cutaneous organ involvement by whole body
positron emission tomography/computed tomography (PET/CT) study. Because LCS is a high-grade malignancy
with poor prognosis, it suggests that strict histological analysis and thorough radiographic examination are
necessary for accurately diagnosing this tumor even if cutaneous involvement presented only.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/6527428618381393
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According to the degree of cytologic atypia and clinical
aggressiveness, Langerhans cell tumors are divided into
two main subgroups: Langerhans cell histiocytosis (LCH)
and Langerhans cell sarcoma (LCS) [1]. LCS is a rare
high-grade neoplasm with overtly malignant cytologic fea-
tures and aggressive clinical course. It can occur at any
age and may involve multiple systems or tissues. Skin and
underlying soft tissue are the most common involvement,
but other unusual locations, such as bone [2], lung [3],
gallbladder and peritoneal lymph nodes [4] have also been
described in the literature. LCS may be limited to cutane-
ous involvement or may progress to affect other organs.
However, to our knowledge, primary cutaneous LCS with-
out any extra-cutaneous association is extremely rare and
so far only a few such cases with immunohistochemical* Correspondence: lizhi@mail.sysu.edu.cn
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reproduction in any medium, provided the orand/or ultrastructural confirmation have been described
in the literature [5,6]. Due to its rareness in skin, the
accurate diagnosis of cutaneous LCS could be difficult to
be made because similar microscopic features may be
encountered in metastatic cancer, malignant melanoma,
anaplastic large cell lymphoma and myeloid sarcoma.
Therefore, it is indeed a challenge for clinicians to make a
correct diagnosis when the LCS presents as a solitary cu-
taneous mass because inaccurate diagnosis may lead to
improper treatment. Herein we describe an additional case
of primary cutaneous LCS arising in the skin in a middle-
aged male patient without any extra-cutaneous manifest-
ation in order to provide valuable information in this field.Case presentation
Clinical presentation and management
A 48-year-old Chinese male visited his local hospital in
May 2010 with a gradually enlarged and ulcerated ery-
thematous plaque on his right knee. The patient stated
that the lesion had been presented on the extensor sidehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with a steroid ointment initially. However, the lesion
gradually enlarged and ulcerated, and a new skin nodule
presented with pain during the last few months. As a re-
sult, the patient was referred to our hospital for examin-
ation and treatment. Physical examination showed 8.0
cm×6.0 cm well-defined ulcerated plaque on the exten-
sor side of his right knee. A solitary nodular mass, meas-
uring 1.5 cm in diameter was also found near the large
ulcerated lesion (Figure 1). There was no weight loss
and no palpable lymphadenopathy or organomegaly.
The laboratory results, including blood count, differen-
tial, liver and renal function, were within the normal
range. A clinically presumed diagnosis was squamous
cell carcinoma of skin. Surgical resection of the skin le-
sion without preoperative skin biopsy was performed.
After diagnosis, the patient underwent polychemother-
apy according to a CHOP protocol (cyclophosphamide,
doxorubicin, oncovin, and prednisone) for six cycles.
The skin ulcerated lesion regressed and the nodule be-
came smaller in size. The patient was on a regular
follow-up period for 12 months after chemotherapy. The
bone marrow examination was performed 6 months
after chemotherapy, but there was no abnormality found.
Since there was a possibility of multiple organs involve-
ment, the patient was referred to a whole body positron
emission tomography/computed tomography (PET/CT)
study to search the potential secondary tumor, but no
abnormality was found. During the period of follow-up,
there was no sign of recurrence of tumor and lymph
node enlargement.
Material and methods
The surgical specimens, including large ulcerated plaque
and small nodular mass, were routinely fixed in 10%Figure 1 Physical examination showed a 8.0 cm×6.0 cm well-
defined ulcerated lesion in the skin of the extensor side of his
right knee. A solitary nodular lesion, measuring 1.5 cm in diameter
was also found near the large ulcerated lesion (black arrow).neutral buffered formalin. The tissues were embedded in
paraffin. Four micrometer-thick sections were stained
with H&E. Immunohistochemical analyses were performed
using the ChemMate Envision/HRP Kit (Dako, Glostrup,
Denmark). The antibodies used in this study included a
broad panel of antibodies against CD1a, CD3, CD5, CD20,
CD21, CD30, CD38, CD56, CD68, CD79a, ALK, S-100
protein, Langerin, pan-cytokeratin, HMB-45, Melan-A,
MPO and ki-67. The antibodies were obtained from Dako
Cytomation (Dako, Glostrup, Denmark), Santa Cruz Bio-
technology (Santa Cruz, CA, USA) and Novocastra labora-
tories LTD (Hong Kong, China).
For detection of Epstein-Barr virus (EBV) infection in
the tissues, in situ hybridization for EBERs (EBV-
encoded RNAs) was performed. The EBERs detection
kit was purchased from Dako (Glostrup, Denmark). The
detection process was conducted according to the man-
ufacturer’s instructions.
Pathological findings
Under microscopic examination, the ulcerated lesion
and solitary skin nodule shared similar histopathological
appearance characterized by diffusely infiltrating of large
tumor cells in dermis and subcutaneous tissue but epi-
dermotropism was not appreciated. The tumor cells
exhibited large epithelioid appearance with abundant eo-
sinophilic cytoplasm and ill-defined cell borders. They
had large oval to convoluted nuclei with nuclear groves
and dispersed chromatin. These cells showed signifi-
cantly malignant cytological features with active mitotic
figure and multinuclear giant cells. Infiltrated neutrophils,
eosinophils and lymphocytes could also been observed
(Figure 2). The immunohistochemistry staining showed
that the tumor cells were diffusely positive for S-100,
CD1a, langerin and CD68, but negative for CD3, CD5,
CD20, CD21, CD30, CD38, CD56, CD79a, ALK, HMB-45,
Melan-A, pan-cytokeratin and MPO. Ki-67 proliferating
index was high approximately 80% (Figure 3). EBERs de-
tection demonstrated that there was no EBV infection in
tumor cells. Taken together, these morphological and im-
munological data were consistent with a cutaneous LCS
according to the WHO diagnostic criteria [1].
Conclusions
Langerhans cell sarcoma (LCS) is a rare but distinct
tumor derived from dendritic cell lineage. It was firstly
recognized by Wood and colleagues in 1984 as malig-
nant histiocytosis X to describe a rapidly fatal cutaneous
mass with massive tumor infiltration of multiple organs
occurring in an elderly male patient [7]. In 1992, Tani
et al. defined it as a “malignant neoplasm of Langerhans
cells with the following criteria: (i) proliferation of typ-
ical Birbeck granule-containing tumor cells, and (ii) ma-
lignant cytological features such as atypia and frequent
Figure 2 Photomicrographs of the cutaneous lesions. (A) Under low-power microscopic examination, the ulcerated lesion showed erosion of
epidermis and diffuse infiltrating of large tumor cells in dermis and subcutaneous tissue. (B) The nodular cutaneous lesion was characterized by
sheets of tumor cells in the dermis but the epidermotropism was not appreciated in the lesion. (C) Tumor cells were large epithelioid with large
oval to convoluted nuclei and nuclear groves. (D) At high-power fields, the tumor cells exhibited significantly malignant cytological features with
ill-defined cell borders and active mitotic figure (A and B, HE staining with original magnification ×40; C, HE staining with original magnification
×200; D, HE staining with original magnification ×400).
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dritic cells is indeed controversial, and there are over-
lapped features among various entities of the histiocytic
and dendritic cell lesions, making definitive diagnosis diffi-
cult [1]. According to the WHO classification, tumors of
dendritic cell lineage include follicular dendritic cell
tumors, interdigitating dendritic cell tumors, Langerhans
cell tumors and other rare dendritic cell tumors. Langer-
hans cells and interdigitating dendritic cells share a
common hematopoietic CD34+ precursor; in contrast, fol-
licular dendritic cells do not have a hematopoietic origin.
Langerhans cell tumors show expression of both CD1a
and S-100 protein, however, interdigitating cells are posi-
tive for S-100 but negative for CD1a. Follicular dendritic
cells express CD21 consistently, but never express CD1a.
These specific immunophenotypes of tumor cells may be
helpful to identify the accurate diagnosis of dendritic celltumors. However, indeterminate dendritic cell tumor, a
rare type of dendritic cell tumor and originate from the
alleged precursor cells of Langerhan cells, is indeed diffi-
cult to distinguish from Langerhans cell tumor because
both tumors consistently express S-100 protein and CD1a.
By definition, indeterminate dendritic cells lack Birbeck
granules on ultrastructural examination [9]. However, not
all cases diagnosed as Langerhans cell tumors had ultra-
structural studies to confirm the presence of Birbeck
granules. Ben-Ezra et al. reported that only 3 cases pre-
sented Birbeck granules among 9 cases of LCS [10].
Deng et al. also described a cutaneous LCS without
Birbeck granules and doubted it might be an indeter-
minate cell sarcoma [11]. Therefore, it is possible that
some previously reported LCS might be confused with
indeterminate cell neoplasms, and indeterminate cell
neoplasms are actually underreported.
Figure 3 Immunohistochemical analysis of the cutaneous lesions showed tumor cells were diffusely positive for largerin (A), CD1a (B)
and S-100 protein (C). (D) Ki-67 proliferating index of tumor cells was high approximately 80%positive (A-D, immunohistochemical staining with
original magnification ×400).
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sents a very specific marker for Langerhans cells and
derived tumors [4,12], and it has been negative in
reported indeterminate cell neoplasms [13,14]. Langerin
is a type II Ca2+-dependent lectin and induces the for-
mation of Birbeck granules, the presence of which sup-
ports a Langerhans cell origin. However, Wang et al.
recently demonstrating a langerin-positive LCS did not
indicate Birbeck granules in the cytoplasm of the neo-
plastic cells on ultrastructural examination [15]. Verdijk
et al. found a lack of Birbeck granules in Langerhans
cells to be associated with a mutation in the langerin
gene [16]. The lack of Birbeck granules under the elec-
tron microscopy might be due to the damage of Birbeck
granules during histological process [3] or poor differen-
tiation of tumor cells [10]. Thus, langerin is a useful
marker for distinguishing Langerhans cell tumors from
indeterminate cell tumors even in Birbeck granules-
negative cases [12,17]. In the present case, we found that
the tumor cells exhibited remarkably cellular atypia andhigher mitotic activity with co-expression of CD1a, S-
100 protein and langerin. This is consistent with a typ-
ical primary LCS in spite of the presence of Birbeck
granules in tumor cells.
Despite its enigmatic histogenesis, LCS is an exceedingly
rare tumor. To the best of our knowledge, only 30 LCS
cases (including the present case) have been reported in
the English-language literature to date [2-8,11,15,18-24].
The age at the time of diagnosis ranged from newborn
[10] to 81 years old [3] without gender bias. LCSs show a
multiple organs involvement. Most of the patients had
lymph node and skin involvement, although the lung,
bone, mediastina, liver, spleen and heart can also be
involved. The skin was the only organ involved in a few
cases [5,6]. Although most LCSs exhibited classical mor-
phological and immunohistochemical features, individual
cases showed unusual appearances, such as aberrant
cytoplasmic CD3 expression and involving epidermis
[15,25]. LCSs are high-grade malignancy and show aggres-
sive clinical course. Chemotherapy regimens have been
Table 1 Clinicopathological features of Langerhans cell sarcoma with only cutaneous involvement described in present and previous reports
No. Authors (yr.) Diagnosis Age (year)/Gender Clinical presentation Immunophenotype EM/MA Treatment Outcome
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various degrees. Radiotherapy has also been applied in
several cases, but the effects remain uncertain. From the
patients for whom follow-up data are available, 53.3% (16/
30) died of their disease within 2 years despite conven-
tional combination chemotherapy, surgery, and radiother-
apy. However, 2 patients of 3 reported LCSs with only
cutaneous involvement survived and were alive in
complete remission (Table 1). In the present case, we
found that the patient achieved a partial remission after
chemotherapy and extra-cutaneous manifestation was not
observed during the period of follow-up, although the
follow-up period was not very long for the patient after
therapy. These findings indicate that primary cutaneous
LCSs without multiple organs involvement might have a
somewhat smoldering stage. Once the tumor progress,
dissemination of extracutaneous sites might be presented
and the patient might gain a poor prognosis with aggres-
sive clinical course. A recent study has demonstrated that
some cases of histiocytic sarcomas do not pursue an ag-
gressive clinical course, particularly cases with clinically
localized disease, and the tumor size appears to be an im-
portant prognostic factor [26]. In addition, Kawase et al.
suggested that CD56+ Langerhans cell neoplasms share
an aggressive clinical behavior and a worse outcome [2].
For our reported patient, the tumor was localized but was
large in size. There was no CD56 expression in tumor
cells. It should carry an unfavorable prognosis. Of course,
long-term follow-up should be performed to verify this
postulation.
As its rareness in skin and poorly differentiated mor-
phologic features, cutaneous LCS should be differentially
diagnosed from other epithelial or mesenchymal malig-
nancy of skin, including metastatic cancer, malignant
melanoma, anaplastic large cell lymphoma and myeloid
sarcoma. All of these diseases exhibit skin lesion and a
frankly malignant cytologic appearance with highly ag-
gressive clinical course and a poor prognosis, which may
sometimes cause diagnostic confusion with LCS. How-
ever, cutaneous squamous cell carcinoma or metastatic
cancer shows an obvious nest structure with epithelial
phenotype, such as pan-cytokeratin, CK7 or CK20. Mel-
anoma might share S-100 protein positivity, but also
expresse other melanocytic markers, such as HMB45 and
melan-A. Anaplastic large cell lymphomas are CD30+
and EMA+ and may show ALK positivity. Occasionally,
myeloid leukemia can firstly present in skin, in which
CD68 and lysozyme positivity could be observed and
sometimes difficult to be distinguished from LCS. The
presence of myeloid specific markers, such as MPO,
CD117, CD99 and CD34 should be helpful in making a
diagnosis of myeloid leukemia first presenting in skin or
cutaneous myeloid sarcoma. In our case, the tumor cells
strongly expressed CD1a, S-100 protein and langerin,which were Langerhans cell-specific marker, arguing
against other cutaneous hematological neoplasma.
In conclusion, LCSs are extremely rare and only a few
cases of LCSs with only cutaneous involvement have
been reported in the literature. Our additive case also
presented its rarity of site. The diagnosis of primary cu-
taneous LCS is difficult and should be made cautiously,
particularly for those cases with clinically localized dis-
ease, but lacking the extra-cutaneous manifestation. LCS
is a highly aggressive hematopoietic malignancy with
poor prognosis. We suggest a long period of follow-up is
necessary and radiographic examination is helpful for
demonstrating organ involvement to inspect the pro-
gression even if the patient had complete remission at
initial chemotherapy.
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